How to Delete SnakeBite911. save (156.00 MB)
Published by BTG plcWe have made it super easy to delete SnakeBite911 account and/or app.
Table of Contents:
Guide to Delete SnakeBite911 👇
Things to note before removing SnakeBite911:
- The developer of SnakeBite911 is BTG plc and all inquiries must go to them.
- Check the Terms of Services and/or Privacy policy of BTG plc to know if they support self-serve subscription cancellation:
- The GDPR gives EU and UK residents a "right to erasure" meaning that you can request app developers like BTG plc to delete all your data it holds. BTG plc must comply within 1 month.
- The CCPA lets American residents request that BTG plc deletes your data or risk incurring a fine (upto $7,500 dollars).
-
Data Not Linked to You: The following data may be collected but it is not linked to your identity:
- Usage Data
- Diagnostics
↪️ Steps to delete SnakeBite911 account:
1: Visit the SnakeBite911 website directly Here →
2: Contact SnakeBite911 Support/ Customer Service:
- 100% Contact Match
- Developer: Protherics Medicines Development Limited
- E-Mail: appledev@btgsp.com
- Website: Visit SnakeBite911 Website
- Support channel
- Vist Terms/Privacy
Deleting from Smartphone 📱
Delete on iPhone:
- On your homescreen, Tap and hold SnakeBite911 until it starts shaking.
- Once it starts to shake, you'll see an X Mark at the top of the app icon.
- Click on that X to delete the SnakeBite911 app.
Delete on Android:
- Open your GooglePlay app and goto the menu.
- Click "My Apps and Games" » then "Installed".
- Choose SnakeBite911, » then click "Uninstall".
Have a Problem with SnakeBite911? Report Issue
🎌 About SnakeBite911
1. Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration.
2. Do not administer CroFab® to patients with a known hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.
3. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction.
4. The new SnakeBite911 app comes from the manufacturers of CroFab® CrotalidaePolyvalent Immune Fab (Ovine), a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation.
5. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).
6. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®.
7. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients.
8. The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain.
9. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment.
10. Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®.
11. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer.
12. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.
13. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.
14. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.
